|
|
.
See Category: Factors influencing health status and contact with health services
See Header: Encounter for screening for malignant neoplasm of oth sites
ICD-10 (CM) Code and Descriptor
|
Z12.83 |
Encounter for screening for malignant neoplasm of skin
This code is considered unacceptable as a principal diagnosis.
|
Z1283 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 20.94%
|
12.77%
|
12.25%
|
12.41%
|
10.64%
|
8.64%
|
6.65%
|
4.84%
|
3.50%
|
2.56%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for Z12.83*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
14,796
|
14,823
|
|
17000
|
DESTRUCT PREMALG LESION |
5,813
|
5,820
|
|
17003
|
DESTRUCT PREMALG LES 2-14 |
4,573
|
12,006
|
|
88305
|
TISSUE EXAM BY PATHOLOGIST |
2,949
|
3,867
|
|
11102
|
TANGNTL BX SKIN SINGLE LES |
2,356
|
2,356
|
|
17110
|
DESTRUCT B9 LESION 1-14 |
1,950
|
1,951
|
|
99214
|
OFFICE O/P EST MOD 30 MIN |
1,479
|
1,479
|
|
99213
|
OFFICE O/P EST LOW 20 MIN |
1,433
|
1,433
|
|
11103
|
TANGNTL BX SKIN EA SEP/ADDL |
704
|
948
|
|
99212
|
OFFICE O/P EST SF 10 MIN |
466
|
467
|
|
G0467
|
FQHC VISIT, ESTAB PT |
414
|
414
|
|
17004
|
DESTROY PREMAL LESIONS 15/> |
402
|
402
|
|
99203
|
OFFICE O/P NEW LOW 30 MIN |
387
|
387
|
|
11104
|
PUNCH BX SKIN SINGLE LESION |
385
|
385
|
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
384
|
385
|
|
88342
|
IMHCHEM/IMCYTCHM 1ST ANTB |
367
|
416
|
|
80053
|
COMPREHEN METABOLIC PANEL |
282
|
282
|
|
85025
|
COMPLETE CBC W/AUTO DIFF WBC |
227
|
227
|
|
88341
|
IMHCHEM/IMCYTCHM EA ADD ANTB |
148
|
284
|
|
80061
|
LIPID PANEL |
148
|
148
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
Z12.83 related to the following DRG Codes:
951
|
